SV

Street Verdict

Analyst Scorecard

A record of what Motilal Oswal Analysis said publicly, with the source. Not advice.

“Maintains a BUY rating on Gland Pharma, expecting a CAGR of 14%, 20%, and 27% in revenue, EBITDA, and net profit over FY25-27, respectively, after three years of decline. The company is strengthening its position in complex injectables and adding capacity for GLP-1 opportunities, supported by strong Q1 earnings.”

Motilal Oswal Analysis’s track record (trackable calls only): 453 graded calls · 95% CI 36–45%

Gland PharmaBullishCalled 06 Aug 2025
Verdict:PENDING

This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.

Read the original articleSee Motilal Oswal Analysis’s full track record